Vendor, South San Francisco, CA
Vaxart Biosciences Inc.
UEI WS6UMD1QTBC9, CAGE 4GQK7
1 award and $9,271,191 obligated between January 12, 2024 and February 2, 2026, 100% under full and open competition, against 1.0 offers on average where reported. 1 of the awards trace back to a SAM.gov solicitation on this site.
Sells to
Awarding agencies by dollars.
| Office of Assistant Secretary for Preparedness and Response | $9,271,191 |
Industries
NAICS on the awards, by dollars.
| Research and Development in Biotechnology (except Nanobiotechnology)NAICS 541714 | $9,271,191 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 1 |
| Definitive Contract | 1 |
Hear when Vaxart Biosciences Inc. wins an award and when a contract it holds is about to end.Follow it
Contracts ending soon
None of Vaxart Biosciences Inc.'s contracts with a published end date ends in the next 19 months.
Competes with
Vendors selling research and development in biotechnology (except nanobiotechnology) to Office of Assistant Secretary for Preparedness and Response, by dollars.
| Advanced Technology InternationalSummerville, SC | $2,764,576,471 |
| Albert B. Sabin Vaccine Institute, Inc. (The)Washington, DC | $356,898,734 |
| Amgen USA Inc.Thousand Oaks, CA | $345,705,117 |
| Start2 Group, Inc.Cambridge, MA | $227,139,021 |
| Siga Technologies, Inc.New York, NY | $177,835,284 |
| Shionogi Inc.Florham Park, NJ | $156,109,904 |
Solicitations it won
SAM.gov opportunities whose award USAspending attributes to this vendor.
- Oral Mucosal Vaccine for SARS-CoV2 Protection
Office of Assistant Secretary for Preparedness and Response, Aspr Administration for Strategic Preparedness and Response
Award noticeSan Francisco, CA75A50124C00002Awarded to Vaxart Biosciences Inc. for $9,271,193
Posted Jan 13, 2024
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75A50124C00002Definitive Contract, January 12, 2024, Full and Open Competition, 1 offersSolicitation | Barda - Aspr / Daappo / Barda DCMAOffice of Assistant Secretary for Preparedness and Response | Clinical Trial Planning Activities for a Phase 2B Clinical Trial That Compares Vaxart'S XBB Vaccine Candidate to an Mrna Comparator to EvaluNAICS 541714, PSC AN42 | $9,271,191 |
- Places of performance
- California
- Product and service codes
- AN42 Health R&D Services; Health Care - Other; Applied Research
- Transactions
- 4 across 1 awards